Parte III: Um doce questionamento: seria o metabolismo de carboidratos o protagonista?
7. IMPLICAÇÕES DOS ACHADOS NO PRESENTE TRABALHO
7.1. A partir das proteínas encontradas diferentemente entre os isolados das formas assintomáticas
e sintomáticas, principalmente a GAPDH, um possível rastreamento dos parasitas presentes na circulação sanguínea possa indicar se um paciente assintomático passará a apresentar sintomatologia e assim iniciar-se um pré-tratamento.
7.2. Servir de suporte para pesquisas de novos fármacos, cujos alvos enzimáticos, bem como o
metabolismo energético para os isolados assintomáticos e a glicólise para os sintomáticos apresentaram maior destaque.
REFERÊNCIAS BIBLIOGRÁFICAS
About Chagas Disease – DNDi. Disponível em: <https://www.dndi.org/diseases-projects/chagas/>.
Acesso em: 15 abr. 2018.
ALVES, C. et al. Pathogenicity of Chagas Disease Cardiopathy. JSM Atheroscler, v. 1, n. 2, 2016. ANDRADE, S. G. et al. Biological, biochemical and molecular features of Trypanosoma cruzi strains isolated from patients infected through oral transmission during a 2005 outbreak in the state of Santa Catarina, Brazil: its correspondence with the new T. cruzi Taxonomy Consensus (2009). Memorias
do Instituto Oswaldo Cruz, v. 106, n. 8, p. 948–56, dez. 2011.
ARROYO-OLARTE, R. D. et al. Complement system contributes to modulate the infectivity of susceptible TcI strains of Trypanosoma cruzi. Memórias do Instituto Oswaldo Cruz, v. 113, n. 4, p. e170332, 19 fev. 2018.
BAKER, Z. N.; COBINE, P. A.; LEARY, S. C. The mitochondrion: a central architect of copper homeostasis. Metallomics, v. 9, n. 11, p. 1501–1512, 15 nov. 2017.
BANDYOPADHYAY, D. et al. A Practical Green Synthesis and Biological Evaluation of Benzimidazoles Against Two Neglected Tropical Diseases: Chagas and Leishmaniasis. Current
Medicinal Chemistry, v. 24, n. 41, 11 jan. 2018.
BARBOSA, M. DAS G. V. et al. Chagas disease in the State of Amazonas: history, epidemiological evolution, risks of endemicity and future perspectives. Revista da Sociedade Brasileira de
Medicina Tropical, v. 48, n. suppl 1, p. 27–33, jun. 2015.
BERN, C. Chagas’ Disease. New England Journal of Medicine, v. 373, n. 5, p. 456–466, 30 jul. 2015.
BRADFORD, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, v. 72, p. 248–54, 7 maio 1976.
BRINGAUD, F.; RIVIÈRE, L.; COUSTOU, V. Energy metabolism of trypanosomatids: Adaptation to available carbon sources. Molecular and Biochemical Parasitology, v. 149, n. 1, p. 1–9, 1 set. 2006.
BRISSE, S.; BARNABÉ, C.; TIBAYRENC, M. Identification of six Trypanosoma cruzi phylogenetic lineages by random amplified polymorphic DNA and multilocus enzyme electrophoresis. International journal for parasitology, v. 30, n. 1, p. 35–44, jan. 2000.
BROSSAS, J.-Y. et al. Secretome analysis of Trypanosoma cruzi by proteomics studies. PLOS ONE, v. 12, n. 10, p. e0185504, 3 out. 2017.
BROUTIN, H. et al. Phylogenetic analysis of the glucose-6-phosphate isomerase gene in
Trypanosoma cruzi. Experimental Parasitology, v. 113, n. 1, p. 1–7, maio 2006.
BUSCAGLIA, C. A. et al. A putative pyruvate dehydrogenase alpha subunit gene from Trypanosoma
cruzi. Biochimica et biophysica acta, v. 1309, n. 1–2, p. 53–7, 11 nov. 1996.
BUSCAGLIA, C. A. et al. Trypanosoma cruzi surface mucins: host-dependent coat diversity. Nature
Reviews Microbiology, v. 4, n. 3, p. 229–236, 1 mar. 2006.
Chagas’ disease. Microbes and infection, v. 5, n. 5, p. 419–27, abr. 2003.
CARRANZA, J. C. et al. Trypanosoma cruzi maxicircle heterogeneity in Chagas disease patients from Brazil. International journal for parasitology, v. 39, n. 9, p. 963–73, 15 jul. 2009.
CASTELLANI, O.; RIBEIRO, L. V.; FERNANDES, J. F. Differentiation of Trypanosoma cruzi in Culture*. The Journal of Protozoology, v. 14, n. 3, p. 447–451, 1 ago. 1967.
CAZZULO, J. J. Energy Metabolism in Trypanosoma cruzi. In: [s.l.] Springer, Boston, MA, 1992. p. 235–257.
CAZZULO, J. J.; SUNDARAM, T. K.; KORNBERG, H. L. Regulation of pyruvate carboxylase formation from the apo-enzyme and biotin in a thermophilic bacillus. Nature, v. 223, n. 5211, p. 1137–8, 13 set. 1969.
CHAGAS, C.; CHAGAS, C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Memórias do Instituto Oswaldo Cruz, v. 1, n. 2, p. 159–218, ago. 1909.
CHATZI, A.; MANGANAS, P.; TOKATLIDIS, K. Oxidative folding in the mitochondrial intermembrane space: A regulated process important for cell physiology and disease. Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research, v. 1863, n. 6, p. 1298–1306, 1 jun. 2016.
CHEN, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.
BMC Bioinformatics, v. 14, n. 1, p. 128, 15 abr. 2013.
CHEVALIER, N. et al. 6-Phosphofructo-2-kinase and fructose-2,6-bisphosphatase in Trypanosomatidae. Molecular characterization, database searches, modelling studies and evolutionary analysis. FEBS Journal, v. 272, n. 14, p. 3542–3560, jul. 2005.
CLEMENTE, P. et al. hCOA3 stabilizes cytochrome c oxidase 1 (COX1) and promotes cytochrome c oxidase assembly in human mitochondria. The Journal of biological chemistry, v. 288, n. 12, p. 8321–31, 22 mar. 2013.
COLASANTE, C. et al. A plant-like mitochondrial carrier family protein facilitates mitochondrial transport of di- and tricarboxylates in Trypanosoma brucei. Molecular and Biochemical
Parasitology, v. 221, p. 36–51, 1 abr. 2018.
COURA, J. R.; VIÑAS, P. A. Chagas disease: a new worldwide challenge. Nature, v. 465, n. n7301_supp, p. S6–S7, 24 jun. 2010.
COX, J. et al. Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment.
Journal of Proteome Research, v. 10, n. 4, p. 1794–1805, 1 abr. 2011.
COX, J.; MANN, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology, v. 26, n. 12, p. 1367–1372, 30 dez. 2008.
CUPELLO, M. P. et al. The heme uptake process in Trypanosoma cruzi epimastigotes is inhibited by heme analogues and by inhibitors of ABC transporters. Acta Tropica, v. 120, n. 3, p. 211–218, dez. 2011.
DAVIES, G.; HENRISSAT, B. Structures and mechanisms of glycosyl hydrolases. Structure, v. 3, n. 9, p. 853–859, 1 set. 1995.
DECAESTECKER, E. et al. Host–parasite ‘Red Queen’ dynamics archived in pond sediment.
Nature, v. 450, n. 7171, p. 870–873, 14 dez. 2007.
DECKERS-HEBESTREIT, G. Assembly of the Escherichia coli F o F 1 ATP synthase involves distinct subcomplex formation. Biochemical Society Transactions, v. 41, n. 5, 2013.
DIAS, J. Epidemiology of Chagas disease. In: S WENDEL, Z BRENER, M S CAMARGO, A. R. (Ed.). . Chagas Disease (American Trypanosomiasis): its Impact on Transfusion and Clinical
Medicine. São Paulo: [s.n.]. p. 49–80.
DIAS, L. et al. Trypanosoma cruzi tryparedoxin II interacts with different peroxiredoxins under physiological and oxidative stress conditions. Experimental Parasitology, v. 184, p. 1–10, 1 jan. 2018.
EL-SAYED, N. M. et al. The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease. Science, v. 309, n. 5733, p. 409–415, 15 jul. 2005.
ELIAS, M. C.; FARIA, M. Are There Epigenetic Controls in Trypanosoma cruzi? Annals of the New
York Academy of Sciences, v. 1178, n. 1, p. 285–290, 1 out. 2009.
ELIGIO-GARCÍA, L. et al. Giardia intestinalis: Expression of ubiquitin, glucosamine-6-phosphate and cyst wall protein genes during the encystment process. Experimental Parasitology, v. 127, n. 2, p. 382–386, fev. 2011.
FERREIRA, B. L. et al. Trypanosoma cruzi: single cell live imaging inside infected tissues. Cellular
microbiology, v. 18, n. 6, p. 779–83, jun. 2016.
FINZI, J. K. et al. Trypanosoma cruzi response to the oxidative stress generated by hydrogen peroxide. Molecular and Biochemical Parasitology, v. 133, n. 1, p. 37–43, 1 jan. 2004.
FLASPOHLER, J. A. et al. Functional identification of a Leishmania gene related to the peroxin 2 gene reveals common ancestry of glycosomes and peroxisomes. Molecular and cellular biology, v. 17, n. 3, p. 1093–101, mar. 1997.
FURUCHÓ, C. R. et al. Inconclusive results in conventional serological screening for Chagas’ disease in blood banks: evaluation of cellular and humoral response. Tropical Medicine &
International Health, v. 13, n. 12, p. 1527–1533, dez. 2008.
GALVANI, A. P. Epidemiology meets evolutionary ecology. Trends in Ecology & Evolution, v. 18, n. 3, p. 132–139, mar. 2003.
GARCÍA-HUERTAS, P. et al. Transcriptome and Functional Genomics Reveal the Participation of Adenine Phosphoribosyltransferase in Trypanosoma cruzi Resistance to Benznidazole. Journal of
Cellular Biochemistry, v. 118, n. 7, p. 1936–1945, jul. 2017.
GARCIA, E. S. et al. Interactions between intestinal compounds of triatomines and Trypanosoma
cruzi. Trends in Parasitology, v. 26, n. 10, p. 499–505, 1 out. 2010.
GINGER, M. L.; SAM, K. A.; ALLEN, J. W. A. Probing why trypanosomes assemble atypical cytochrome c with an AxxCH haem-binding motif instead of CxxCH. The Biochemical journal, v. 448, n. 2, p. 253–60, 1 dez. 2012.
GNIPOVÁ, A. et al. Disparate phenotypic effects from the knockdown of various Trypanosoma
90–98, 1 ago. 2012.
GUHL, F.; AUDERHEIDE, A.; RAMÍREZ, J. D. From ancient to contemporary molecular eco- epidemiology of Chagas disease in the Americas. International Journal for Parasitology, v. 44, n. 9, p. 605–612, 1 ago. 2014.
GUTIÉRREZ-CORREA, J. Trypanosoma cruzi dihydrolipoamide dehydrogenase as target of reactive metabolites generated by cytochrome c/hydrogen peroxide (or linoleic acid hydroperoxide)/phenol systems. Free Radical Research, v. 44, n. 11, p. 1345–1358, 6 nov. 2010. HALL, B. S.; WILKINSON, S. R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrobial agents and chemotherapy, v. 56, n. 1, p. 115–23, jan. 2012.
HAUSER, R. et al. In vitro import of proteins into mitochondria of Trypanosoma brucei and
Leishmania tarentolae. Journal of cell science, v. 109 ( Pt 2), p. 517–23, fev. 1996.
HEALY, N. et al. Detection of peptidases in Trypanosoma cruzi epimastigotes using chromogenic and fluorogenic substrates. Parasitology, v. 104, n. 02, p. 315, 6 abr. 1992.
HEBERLE, H. et al. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams.
BMC Bioinformatics, v. 16, n. 1, p. 169, 22 dez. 2015.
HENRIQUE, P. M. et al. Correlation between the virulence of T. cruzi strains, complement regulatory protein expression levels, and the ability to elicit lytic antibody production. Experimental
Parasitology, v. 170, p. 66–72, 1 nov. 2016.
HENRIQUES, C. et al. In vivo imaging of mice infected with bioluminescent Trypanosoma cruzi unveils novel sites of infection. Parasites & vectors, v. 7, p. 89, 3 mar. 2014.
HUYNEN, M. A. et al. Evolution and structural organization of the mitochondrial contact site (MICOS) complex and the mitochondrial intermembrane space bridging (MIB) complex. Biochimica
et Biophysica Acta (BBA) - Molecular Cell Research, v. 1863, n. 1, p. 91–101, 1 jan. 2016.
IGOILLO-ESTEVE, M. et al. The pentose phosphate pathway in Trypanosoma cruzi: a potential target for the chemotherapy of Chagas disease. Anais da Academia Brasileira de Ciências, v. 79, n. 4, p. 649–663, dez. 2007.
JANKE, R.; DODSON, A. E.; RINE, J. Metabolism and Epigenetics. Annual Review of Cell and
Developmental Biology, v. 31, n. 1, p. 473–496, 13 nov. 2015.
KAWAHARA, R. et al. Deciphering the Role of the ADAM17-Dependent Secretome in Cell Signaling. Journal of Proteome Research, v. 13, n. 4, p. 2080–2093, 4 abr. 2014.
KULESHOV, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research, v. 44, n. W1, p. W90–W97, 8 jul. 2016.
LATTES, R.; LASALA, M. B. Chagas disease in the immunosuppressed patient. Clinical
Microbiology and Infection, v. 20, n. 4, p. 300–309, abr. 2014.
LEANDRO DE JESUS, T. C. et al. Quantitative Proteomic Analysis of Replicative and Nonreplicative Forms Reveals Important Insights into Chromatin Biology of Trypanosoma cruzi.
Molecular & cellular proteomics : MCP, v. 16, n. 1, p. 23–38, 1 jan. 2017.
systems. [s.l: s.n.].
LEE, J. et al. NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype. Yonsei medical
journal, v. 54, n. 5, p. 1158–67, set. 2013.
LEROUX, A. E. et al. Comparative studies on the biochemical properties of the malic enzymes from Trypanosoma cruzi and Trypanosoma brucei. FEMS Microbiology Letters, v. 314, n. 1, p. 25– 33, jan. 2011.
LEWIS, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection.
Cellular microbiology, v. 16, n. 9, p. 1285–300, set. 2014.
LIMA, L. et al. Genetic diversity of Trypanosoma cruzi in bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as an independent DTU (discrete typing unit). Acta
Tropica, v. 151, p. 166–177, 1 nov. 2015.
LOBO-ROJAS, Á. E. et al. Trypanosoma cruzi contains two galactokinases; molecular and biochemical characterization. Parasitology International, v. 65, n. 5, p. 472–482, out. 2016. LUX, H. et al. Ether–lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether– lipid analogues in Leishmania. Molecular and Biochemical Parasitology, v. 111, n. 1, p. 1–14, 1 nov. 2000.
MACEDO, A. M. et al. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease. Memórias do Instituto Oswaldo Cruz, v. 99, n. 1, p. 1–12, fev. 2004.
MANNE-GOEHLER, J. Chagas Disease in the United States: Out of the Shadows. Clinical
Infectious Diseases, v. 64, n. 9, p. 1189–1190, 1 maio 2017.
MAUGERI, D. A.; CANNATA, J. J. B.; CAZZULO, J.-J. Glucose metabolism in Trypanosoma
cruzi. Essays in biochemistry, v. 51, p. 15–30, 24 out. 2011.
MCCALL, L.-I. et al. Adaptation of Leishmania donovani to Cutaneous and Visceral Environments: in Vivo Selection and Proteomic Analysis. Journal of Proteome Research, v. 14, n. 2, p. 1033– 1059, 6 fev. 2015.
MERCALDI, G. F. et al. The structure of a Trypanosoma cruzi glucose-6-phosphate dehydrogenase reveals differences from the mammalian enzyme. FEBS Letters, v. 590, n. 16, p. 2776–2786, ago. 2016.
MESQUITA, R. D. et al. Genome of Rhodnius prolixus, an insect vector of Chagas disease, reveals unique adaptations to hematophagy and parasite infection. Proceedings of the National Academy
of Sciences of the United States of America, v. 112, n. 48, p. 14936–41, 1 dez. 2015.
MESSENGER, L. A.; MILES, M. A.; BERN, C. Expert Review of Anti-infective Therapy Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev. Anti Infect. Ther, v. 13, n. 8, p. 995–1029, 2015.
MEYMANDI, S. K. et al. Prevalence of Chagas Disease in the Latin American–born Population of Los Angeles. Clinical Infectious Diseases, v. 64, n. 9, p. 1182–1188, 1 maio 2017.
MICHELS, P. A. M. et al. Metabolic functions of glycosomes in trypanosomatids. Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research, v. 1763, n. 12, p. 1463–1477, 1 dez. 2006.
MIELNICZKI-PEREIRA, A. A. et al. Trypanosoma cruzi strains, Tulahuen 2 and Y, besides the difference in resistance to oxidative stress, display differential glucose-6-phosphate and 6- phosphogluconate dehydrogenases activities. Acta Tropica, v. 101, n. 1, p. 54–60, jan. 2007. MIGUEL, D. C. et al. Clinical isolates of New World Leishmania from cutaneous and visceral leishmaniasis patients are uniformly sensitive to tamoxifen. International journal of antimicrobial
agents, v. 38, n. 1, p. 93–4, 1 jul. 2011.
MORENO, M. et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz Rio de Janeiro, v. 105, n. 7, p. 918–924, 2010.
MÜLLER, S.; CERDAN, R.; RADULESCU, O. Comprehensive analysis of parasite biology :
from metabolism to drug discovery. [s.l: s.n.].
NARDY, A. F. F. R. et al. Role of Trypanosoma cruzi Trans-sialidase on the Escape from Host Immune Surveillance. Frontiers in Microbiology, v. 7, p. 348, 23 mar. 2016.
NEWSHOLME, E. A.; CARRIE, A.-L. Quantitive aspects of glucose and glutamine metabolism by intestinal cells. Gut, v. 1, p. 13–17, 1994.
NIYOGI, S. et al. Rab32 is essential for maintaining functional acidocalcisomes, and for growth and infectivity of Trypanosoma cruzi. Journal of cell science, v. 128, n. 12, p. 2363–73, 15 jun. 2015. NOCENTINI, A. et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani
chagasi are inhibited by benzoxaboroles. Journal of Enzyme Inhibition and Medicinal Chemistry,
v. 33, n. 1, p. 286–289, 27 jan. 2018.
NORRIS, K. A.; SCHRIMPF, J. E. Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi. Infection and immunity, v. 62, n. 1, p. 236– 43, jan. 1994.
OBERG, A. L.; VITEK, O. Statistical Design of Quantitative Mass Spectrometry-Based Proteomic Experiments. Journal of Proteome Research, v. 8, n. 5, p. 2144–2156, maio 2009.
OLIVEIRA, I. A. et al. Trypanosoma cruzi Trans-Sialidase: Structural Features and Biological Implications. In: [s.l.] Springer, Dordrecht, 2014. p. 181–201.
OLSON, L. J.; DAHMS, N. M. Mannose 6-Phosphate Receptors. In: Glycoscience: Biology and
Medicine. Tokyo: Springer Japan, 2015. p. 1037–1047.
PABA, J. et al. Proteomic analysis of the human pathogenTrypanosoma cruzi. PROTEOMICS, v. 4, n. 4, p. 1052–1059, 1 abr. 2004.
PAHO WHO | General Information - Chagas Disease. Disponível em:
<http://www.paho.org/hq/index.php?option=com_content&view=article&id=5856&Itemid=41506 &lang=en>. Acesso em: 17 abr. 2018.
PARIONA-LLANOS, R. et al. Glyceraldehyde 3-Phosphate Dehydrogenase-Telomere Association Correlates with Redox Status in Trypanosoma cruzi. PLOS ONE, v. 10, n. 3, p. e0120896, 16 mar. 2015.
PEDRO J. ALCOLEA, ANA ALONSO, V. L. Genome-wide gene expression profile induced by exposure to cadmium acetate in Leishmania infantum promastigotes. [s.d.].
PENHA, L. L. et al. Sorting of phosphoglucomutase to glycosomes in Trypanosoma cruzi is mediated by an internal domain. Glycobiology, v. 19, n. 12, p. 1462–1472, 1 dez. 2009.
PEREIRA, K. S. et al. Chagas’ Disease as a Foodborne Illness. Journal of Food Protection, v. 72, n. 2, p. 441–446, 2009.
PÉREZ-MOLINA, J. A. et al. Old and new challenges in Chagas disease. The Lancet Infectious
Diseases, v. 15, n. 11, p. 1347–1356, 1 nov. 2015.
PINAZO, M.-J. et al. Immunosuppression and Chagas Disease: A Management Challenge. PLoS
Neglected Tropical Diseases, v. 7, n. 1, p. e1965, 17 jan. 2013.
PINAZO, M.-J. et al. Characterization of Digestive Involvement in Patients with Chronic T. cruzi Infection in Barcelona, Spain. PLoS Neglected Tropical Diseases, v. 8, n. 8, p. e3105, 21 ago. 2014. PINEDA, E. et al. Pyruvate:ferredoxin oxidoreductase and bifunctional aldehyde-alcohol dehydrogenase are essential for energy metabolism under oxidative stress in Entamoeba histolytica.
FEBS Journal, v. 277, n. 16, p. 3382–3395, ago. 2010.
PINNELL, J.; TURNER, S.; HOWELL, S. Cardiac muscle physiology. Continuing Education in
Anaesthesia Critical Care & Pain, v. 7, n. 3, p. 85–88, 1 jun. 2007.
PORTAL, P. et al. Multiple NADPH–cytochrome P450 reductases from Trypanosoma cruzi: Suggested role on drug resistance. Molecular and Biochemical Parasitology, v. 160, n. 1, p. 42–51, 1 jul. 2008.
RABAJANTE, J. F. et al. Red Queen dynamics in multi-host and multi-parasite interaction system.
Scientific Reports, v. 5, n. 1, p. 10004, 22 set. 2015.
RAMÍREZ, J. D. et al. Validation of a Poisson-distributed limiting dilution assay (LDA) for a rapid and accurate resolution of multiclonal infections in natural Trypanosoma cruzi populations. Journal
of Microbiological Methods, v. 92, n. 2, p. 220–225, 15 fev. 2013.
RANZANI, A. et al. Identification of Specific Inhibitors of Trypanosoma cruzi Malic Enzyme Isoforms by Target-Based HTS. [s.d.].
RAPPSILBER, J.; MANN, M.; ISHIHAMA, Y. Protocol for micro-purification, enrichment, pre- fractionation and storage of peptides for proteomics using StageTips. Nature Protocols, v. 2, n. 8, p. 1896–1906, ago. 2007.
RASSI, A.; RASSI, A.; MARIN-NETO, J. A. Chagas disease. The Lancet, v. 375, n. 9723, p. 1388– 1402, 17 abr. 2010.
RIBEIRO, A. L. et al. Diagnosis and management of Chagas disease and cardiomyopathy. Nature
Reviews Cardiology, v. 9, n. 10, p. 576–589, 31 jul. 2012.
ROEDIGER, W. E. W. Utilization of Nutrients by Isolated Epithelial Cells of the Rat Colon.
GASTROENTEROLOGY, v. 83, p. 424–9, 1982.
RONDÓN-MERCADO, R. et al. Subcellular localization of glycolytic enzymes and characterization of intermediary metabolism of Trypanosoma rangeli. Molecular and Biochemical Parasitology, v. 216, p. 21–29, set. 2017.
ROPER, J. R.; FERGUSON, M. A. J. Cloning and characterisation of the UDP-glucose 4’-epimerase of Trypanosoma cruzi. Molecular and biochemical parasitology, v. 132, n. 1, p. 47–53, nov. 2003. RUIZ DÍAZ, P. et al. Trypanosoma cruzi trans-sialidase prevents elicitation of Th1 cell response via interleukin 10 and downregulates Th1 effector cells. Infection and immunity, v. 83, n. 5, p. 2099– 108, maio 2015.
SABINO, E. C. et al. Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time. Transfusion, v. 53, n. 6, p. 1257–1265, 1 jun. 2013.
SALOMONE, O. A. et al. Trypanosoma cruzi in persons without serologic evidence of disease, Argentina. Emerging infectious diseases, v. 9, n. 12, p. 1558–62, dez. 2003.
SANCHES, T. L. M. et al. The Use of a Heterogeneously Controlled Mouse Population Reveals a Significant Correlation of Acute Phase Parasitemia with Mortality in Chagas Disease. PLoS ONE, v. 9, n. 3, p. e91640, 20 mar. 2014.
SARAIVA, V. B. et al. Na+-ATPase and protein kinase C are targets to 1-O-hexadecylphosphocoline (miltefosine) in Trypanosoma cruzi. Archives of Biochemistry and Biophysics, v. 481, n. 1, p. 65– 71, jan. 2009.
SCHMUNIS, G. A. SciELO Books / SciELO Livros / SciELO Libros. [s.d.].
SHIKANAI-YASUDA, M. A.; CARVALHO, N. B. Oral Transmission of Chagas Disease. Clinical
Infectious Diseases, v. 54, n. 6, p. 845–852, 15 mar. 2012.
SILBER, A. M. et al. Glucose uptake in the mammalian stages of Trypanosoma cruzi. Molecular
and Biochemical Parasitology, v. 168, n. 1, p. 102–108, nov. 2009.
SILVA-DOS-SANTOS, D. et al. Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. PLOS Neglected Tropical Diseases, v. 11, n. 4, p. e0005507, 5 abr. 2017.
SILVA, T. M. et al. O2 consumption rates along the growth curve: new insights into Trypanosoma
cruzi mitochondrial respiratory chain. Journal of Bioenergetics and Biomembranes, v. 43, n. 4, p.
409–417, 6 ago. 2011.
SOPRANO, L. L. et al. Trypanosoma cruzi serinecarboxipeptidase is a sulfated glycoprotein and a minor antigen in human Chagas disease infection. Medical Microbiology and Immunology, v. 207, n. 2, p. 117–128, 22 abr. 2018.
STEINDEL, M. et al. Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. Diagnostic microbiology and infectious disease, v. 60, n. 1, p. 25–32, jan. 2008.
STENMARK, P. et al. A new member of the family of di-iron carboxylate proteins. Coq7 (clk-1), a membrane-bound hydroxylase involved in ubiquinone biosynthesis. The Journal of biological
chemistry, v. 276, n. 36, p. 33297–300, 7 set. 2001.
STENSETH, N. C.; SMITH, J. M. COEVOLUTION IN ECOSYSTEMS: RED QUEEN EVOLUTION OR STASIS? Evolution, v. 38, n. 4, p. 870–880, 1 jul. 1984.
v. 75p. 169–192.
STOCO, P. H. et al. Trypanosoma rangeli expresses a β-galactofuranosyl transferase. Experimental
Parasitology, v. 130, n. 3, p. 246–252, 1 mar. 2012.
TOSO M, A.; VIAL U, F.; GALANTI, N. [Oral transmission of Chagas’ disease]. Revista medica
de Chile, v. 139, n. 2, p. 258–66, fev. 2011.
URBINA, J. A. Chemotherapy of Chagas disease. Current pharmaceutical design, v. 8, n. 4, p. 287–95, 2002.
URBINA, J. A.; DOCAMPO, R. Specific chemotherapy of Chagas disease: controversies and advances. Trends in parasitology, v. 19, n. 11, p. 495–501, 1 nov. 2003.
VALEN, L. VAN. A New Evolutionary Law. Evolutionary Theory, v. 1, p. 1–30, 1973.
VAZQUEZ, B. P. et al. Inflammatory responses and intestinal injury development during acute
Trypanosoma cruzi infection are associated with the parasite load. Parasites & Vectors, v. 8, n. 1, p.
206, 3 dez. 2015.
VENKATESH, D. et al. Evolution of the endomembrane systems of trypanosomatids - conservation and specialisation. Journal of cell science, v. 130, n. 8, p. 1421–1434, 2017.
VERLINDE, C. L. M. J. et al. Glycolysis as a target for the design of new anti-trypanosome drugs.
Drug Resistance Updates, v. 4, n. 1, p. 50–65, 1 fev. 2001.
VILLÉN, J.; GYGI, S. P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nature Protocols, v. 3, n. 10, p. 1630–1638, set. 2008.
WANG, J. et al. Structure and function of the catalytic domain of the dihydrolipoyl acetyltransferase component in Escherichia coli pyruvate dehydrogenase complex. The Journal of biological
chemistry, v. 289, n. 22, p. 15215–30, 30 maio 2014.
WHO. Working to overcome the global impact of neglected tropical diseases. 2011. WHO. Weekly epidemiological record Relevé épidémiologique hebdomadaire. 2015.
WILKINS, M. R. et al. From proteins to proteomes: large scale protein identification by two- dimensional electrophoresis and amino acid analysis. Bio/technology (Nature Publishing
Company), v. 14, n. 1, p. 61–5, jan. 1996.
WILKINS, M. R. et al. Guidelines for the next 10 years of proteomics. PROTEOMICS, v. 6, n. 1, p. 4–8, 1 jan. 2006.
YEO, M. et al. Origins of Chagas disease: Didelphis species are natural hosts of Trypanosoma cruzi I and armadillos hosts of Trypanosoma cruzi II, including hybrids. International Journal for
Parasitology, v. 35, n. 2, p. 225–233, 1 fev. 2005.
YUZYUK, T. et al. Galactose-1-Phosphate Uridyltransferase Activities in Different Genotypes: A Retrospective Analysis of 927 Samples. The Journal of Applied Laboratory Medicine, p. jalm.2017.025536, 28 fev. 2018.
ZHUO, Y. et al. Dynamic nuclear polarization facilitates monitoring of pyruvate metabolism in
Trypanosoma brucei. Journal of Biological Chemistry, v. 292, n. 44, p. 18161–18168, 3 nov. 2017.
revision meeting recommends TcI to TcVI. Memorias do Instituto Oswaldo Cruz, v. 104, n. 7, p. 1051–4, nov. 2009.
ZINGALES, B. Trypanosoma cruzi: um parasita, dois parasitas ou vários parasitas da doença de chagas? Revista da Biologia, v. 6b, p. 44–48, jun. 2011.
ZINGALES, B. et al. The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications. Infection, Genetics and Evolution, v. 12, n. 2, p. 240–253, mar. 2012.
ZINGALES, B. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Tropica, 21 set. 2017.